Le informazioni sugli articoli di fonte ISI sono coperte da copyright

Per ulteriori informazioni selezionare i riferimenti di interesse.

1. Freyer, G; Rougier, P; Bugat, R; Droz, JP; Marty, M; Bleiberg, H; Mignard, D; Awad, L; Herait, P; Culine, S; Trillet-Lenoir, V
   Prognostic factors for tumour response, progression-free survival and toxicity in metastatic colorectal cancer patients given irinotecan (CPT-11) as second-line chemotherapy after 5FU failure
   BRITISH JOURNAL OF CANCER
   
   G. Freyer et al., "Prognostic factors for tumour response, progression-free survival and toxicity in metastatic colorectal cancer patients given irinotecan (CPT-11) as second-line chemotherapy after 5FU failure", BR J CANC, 83(4), 2000, pp. 431-437
2. Van Cutsem, E; Cunningham, D; Huinink, WWT; Punt, CJA; Alexopoulos, CG; Dirix, L; Symann, M; Blijham, GH; Cholet, P; Fillet, G; Van Groeningen, C; Vannetzel, JM; Levi, F; Panagos, G; Unger, C; Wils, J; Cote, C; Blanc, C; Herait, P; Bleiberg, H
   Clinical activity and benefit of irinotecan (CPT-11) in patients with colorectal cancer truly resistant to 5-fluorouracil (5-FU)
   EUROPEAN JOURNAL OF CANCER
   
   E. Van Cutsem et al., "Clinical activity and benefit of irinotecan (CPT-11) in patients with colorectal cancer truly resistant to 5-fluorouracil (5-FU)", EUR J CANC, 35(1), 1999, pp. 54-59
3. WASSERMAN E; MYARA A; LOKIEC F; RIOFRIO M; IMADALOU K; BLEUZEN P; SANTONI J; TRIVIN F; HERAIT P; MAHJOUBI M; ARMAND JP; MISSET JL; CVITKOVIC E
   BILIRUBIN (BIL) AND SN-38 - PHARMACOKINETIC PHARMACODYNAMICS CORRELATION/
   Annals of oncology
   
   E. Wasserman et al., "BILIRUBIN (BIL) AND SN-38 - PHARMACOKINETIC PHARMACODYNAMICS CORRELATION/", Annals of oncology, 9, 1998, pp. 220-220
4. SALIBA F; HAGIPANTELLI R; MISSET JL; BASTIAN G; VASSAL G; BONNAY M; HERAIT P; COTE C; MAHJOUBI M; MIGNARD D; CVITKOVIC E
   PATHOPHYSIOLOGY AND THERAPY OF IRINOTECAN-INDUCED DELAYED-ONSET DIARRHEA IN PATIENTS WITH ADVANCED COLORECTAL-CANCER - A PROSPECTIVE ASSESSMENT
   Journal of clinical oncology
   
   F. Saliba et al., "PATHOPHYSIOLOGY AND THERAPY OF IRINOTECAN-INDUCED DELAYED-ONSET DIARRHEA IN PATIENTS WITH ADVANCED COLORECTAL-CANCER - A PROSPECTIVE ASSESSMENT", Journal of clinical oncology, 16(8), 1998, pp. 2745-2751
5. ROUGIER P; VANCUTSEM E; BAJETTA E; NIEDERLE N; POSSINGER K; LABIANCA R; NAVARRO M; MORANT R; BLEIBERG H; WILS J; AWAD L; HERAIT P; JACQUES C
   RANDOMIZED TRIAL OF IRINOTECAN VERSUS FLUOROURACIL BY CONTINUOUS-INFUSION AFTER FLUOROURACIL FAILURE IN PATIENTS WITH METASTATIC COLORECTAL-CANCER
   Lancet
   
   P. Rougier et al., "RANDOMIZED TRIAL OF IRINOTECAN VERSUS FLUOROURACIL BY CONTINUOUS-INFUSION AFTER FLUOROURACIL FAILURE IN PATIENTS WITH METASTATIC COLORECTAL-CANCER", Lancet, 352(9138), 1998, pp. 1407-1412
6. CUNNINGHAM D; PYRHONEN S; JAMES RD; PUNT CJA; HICKISH TF; HEIKKILA R; JOHANNESEN TB; STARKHAMMAR H; TOPHAM CA; AWAD L; JACQUES C; HERAIT P
   RANDOMIZED TRIAL OF IRINOTECAN PLUS SUPPORTIVE CARE VERSUS SUPPORTIVECARE ALONE AFTER FLUOROURACIL FAILURE FOR PATIENTS WITH METASTATIC COLORECTAL-CANCER
   Lancet
   
   D. Cunningham et al., "RANDOMIZED TRIAL OF IRINOTECAN PLUS SUPPORTIVE CARE VERSUS SUPPORTIVECARE ALONE AFTER FLUOROURACIL FAILURE FOR PATIENTS WITH METASTATIC COLORECTAL-CANCER", Lancet, 352(9138), 1998, pp. 1413-1418
7. BLIJHAM G; SCHMITT C; AUSSAGE P; HENRYLAUNOIS B; JOLAIN B; HERAIT P
   COST-EFFECTIVENESS OF IRINOTECAN (CPT-11) AND BEST ESTIMATED CHEMOTHERAPY REGIMEN IN PATIENTS WITH METASTATIC COLORECTAL-CANCER AFTER FAILURE OF 5FLUOROURACIL (5FU) CONTAINING REGIMEN - RESULTS BASED ON A PHASE-III TRIAL
   European journal of cancer
   
   G. Blijham et al., "COST-EFFECTIVENESS OF IRINOTECAN (CPT-11) AND BEST ESTIMATED CHEMOTHERAPY REGIMEN IN PATIENTS WITH METASTATIC COLORECTAL-CANCER AFTER FAILURE OF 5FLUOROURACIL (5FU) CONTAINING REGIMEN - RESULTS BASED ON A PHASE-III TRIAL", European journal of cancer, 33, 1997, pp. 4-4
8. WASSERMAN E; MYARA A; RIOFRIO M; PAUMIER D; HERAIT P; AWAD L; MISSET JL; CVITKOVIC E
   BILIRUBIN - BASE-LINE VALUE AND TRANSIENT INCREASE OF TOTAL BILIRUBIN(BIL) MAY BE USED AS GOOD PREDICTOR OF CPT-11S TOXICITY
   European journal of cancer
   
   E. Wasserman et al., "BILIRUBIN - BASE-LINE VALUE AND TRANSIENT INCREASE OF TOTAL BILIRUBIN(BIL) MAY BE USED AS GOOD PREDICTOR OF CPT-11S TOXICITY", European journal of cancer, 33, 1997, pp. 1110-1110
9. SASTRE J; PAZARES L; DIAZRUBIO E; CORTESFUNES H; CARCAS A; GRUIA G; HERAIT P; FDZCHACON C; MARTIN C; FARR I
   PHASE-I DOSE-FINDING STUDY OF IRINOTECAN (CPT-11) OVER A SHORT IV INFUSION COMBINED WITH A FIXED-DOSE OF 5-FLUOROURACIL (5-FU) PROTRACTED CONTINUOUS IV INFUSION IN PATIENTS WITH ADVANCED SOLID TUMORS
   European journal of cancer
   
   J. Sastre et al., "PHASE-I DOSE-FINDING STUDY OF IRINOTECAN (CPT-11) OVER A SHORT IV INFUSION COMBINED WITH A FIXED-DOSE OF 5-FLUOROURACIL (5-FU) PROTRACTED CONTINUOUS IV INFUSION IN PATIENTS WITH ADVANCED SOLID TUMORS", European journal of cancer, 33, 1997, pp. 1141-1141
10. MERROUCHE Y; EXTRA JM; ABIGERGES D; BUGAT R; CATIMEL G; SUC E; MARTY M; HERAIT P; MAHJOUBI M; ARMAND JP
    HIGH DOSE-INTENSITY OF IRINOTECAN ADMINISTERED EVERY 3 WEEKS IN ADVANCED CANCER-PATIENTS - A FEASIBILITY STUDY
    Journal of clinical oncology
    
    Y. Merrouche et al., "HIGH DOSE-INTENSITY OF IRINOTECAN ADMINISTERED EVERY 3 WEEKS IN ADVANCED CANCER-PATIENTS - A FEASIBILITY STUDY", Journal of clinical oncology, 15(3), 1997, pp. 1080-1086
11. ROUGIER P; BUGAT R; DOUILLARD JY; CULINE S; SUC E; BRUNET P; BECOUARN Y; YCHOU M; MARTY M; EXTRA JM; BONNETERRE J; ADENIS A; SEITZ JF; GANEM G; NAMER M; CONROY T; NEGRIER S; MERROUCHE Y; BURKI F; MOUSSEAU M; HERAIT P; MAHJOUBI M
    PHASE-II STUDY OF IRINOTECAN IN THE TREATMENT OF ADVANCED COLORECTAL-CANCER IN CHEMOTHERAPY-NAIVE PATIENTS AND PATIENTS PRETREATED WITH FLUOROURACIL-BASED CHEMOTHERAPY
    Journal of clinical oncology
    
    P. Rougier et al., "PHASE-II STUDY OF IRINOTECAN IN THE TREATMENT OF ADVANCED COLORECTAL-CANCER IN CHEMOTHERAPY-NAIVE PATIENTS AND PATIENTS PRETREATED WITH FLUOROURACIL-BASED CHEMOTHERAPY", Journal of clinical oncology, 15(1), 1997, pp. 251-260
12. CANAL P; GAY C; DEZEUZE A; DOUILLARD JY; BUGAT R; BRUNET R; ADENIS A; HERAIT P; LOKIEC F; MATHIEUBOUE A
    PHARMACOKINETICS AND PHARMACODYNAMICS OF IRINOTECAN DURING A PHASE-IICLINICAL-TRIAL IN COLORECTAL-CANCER
    Journal of clinical oncology
    
    P. Canal et al., "PHARMACOKINETICS AND PHARMACODYNAMICS OF IRINOTECAN DURING A PHASE-IICLINICAL-TRIAL IN COLORECTAL-CANCER", Journal of clinical oncology, 14(10), 1996, pp. 2688-2695
13. ARMAND JP; DUCREUX M; MAHJOUBI M; ABIGERGES D; BUGAT R; CHABOT G; HERAIT P; DEFORNI M; ROUGIER P
    CPT-II (IRINOTECAN) IN THE TREATMENT OF COLORECTAL-CANCER
    European journal of cancer
    
    J.P. Armand et al., "CPT-II (IRINOTECAN) IN THE TREATMENT OF COLORECTAL-CANCER", European journal of cancer, 31A(7-8), 1995, pp. 1283-1287
14. MISSET JL; SALIBA F; GIACCHETTI S; BRAIN E; VASSAL G; BONNAY M; BASTIAN G; COTE C; MAHJOUBI M; HERAIT P; HAGIPANTELLI R; CVITKOVIC E
    PATHOPHYSIOLOGY AND THERAPY OF IRINOTECAN (CPT-11) INDUCED DELAYED-ONSET DIARRHEA (DD) - A PROSPECTIVE ASSESSMENT
    European journal of cancer
    
    J.L. Misset et al., "PATHOPHYSIOLOGY AND THERAPY OF IRINOTECAN (CPT-11) INDUCED DELAYED-ONSET DIARRHEA (DD) - A PROSPECTIVE ASSESSMENT", European journal of cancer, 31A, 1995, pp. 742-742
15. CHABOT GG; ABIGERGES D; CATIMEL G; CULINE S; DEFORNI R; EXTRA JM; MAHJOUBI H; HERAIT P; ARMAND JP; BUGAT R; CLAVEL M; MARTY ME
    POPULATION PHARMACOKINETICS AND PHARMACODYNAMICS OF IRINOTECAN (CPT-11) AND ACTIVE METABOLITE SN-38 DURING PHASE-I TRIALS
    Annals of oncology
    
    G.G. Chabot et al., "POPULATION PHARMACOKINETICS AND PHARMACODYNAMICS OF IRINOTECAN (CPT-11) AND ACTIVE METABOLITE SN-38 DURING PHASE-I TRIALS", Annals of oncology, 6(2), 1995, pp. 141-151
16. ABIGERGES D; CHABOT GG; ARMAND JP; HERAIT P; GOUYETTE A; GANDIA D
    PHASE-I AND PHARMACOLOGICAL STUDIES OF THE CAMPTOTHECIN ANALOG IRINOTECAN ADMINISTERED EVERY 3 WEEKS IN CANCER-PATIENTS
    Journal of clinical oncology
    
    D. Abigerges et al., "PHASE-I AND PHARMACOLOGICAL STUDIES OF THE CAMPTOTHECIN ANALOG IRINOTECAN ADMINISTERED EVERY 3 WEEKS IN CANCER-PATIENTS", Journal of clinical oncology, 13(1), 1995, pp. 210-221
17. MUNCK JN; ROUGIER P; CHABOT GG; RAMIREZ LH; BOGNEL C; LUMBROSO J; HERAIT P; ELIAS D; LASSER P; GOUYETTE A
    PHASE-I AND PHARMACOLOGICAL STUDY OF INTRAARTERIAL HEPATIC ADMINISTRATION OF PIRARUBICIN IN PATIENTS WITH ADVANCED HEPATIC METASTASES
    European journal of cancer
    
    J.N. Munck et al., "PHASE-I AND PHARMACOLOGICAL STUDY OF INTRAARTERIAL HEPATIC ADMINISTRATION OF PIRARUBICIN IN PATIENTS WITH ADVANCED HEPATIC METASTASES", European journal of cancer, 30A(3), 1994, pp. 289-294
18. MAHJOUBI M; ROUGIER P; OLIVIERA J; HERAIT P; TIGAUD JM; DROZ JP
    PHASE-II TRIAL OF PIRARUBICIN IN THE TREATMENT OF ADVANCED PANCREATIC-CANCER
    Cancer investigation
    
    M. Mahjoubi et al., "PHASE-II TRIAL OF PIRARUBICIN IN THE TREATMENT OF ADVANCED PANCREATIC-CANCER", Cancer investigation, 12(4), 1994, pp. 403-405
19. ABIGERGES D; ARMAND JP; CHABOT GG; DACOSTA L; FADEL E; COTE C; HERAIT P; GANDIA D
    IRINOTECAN (CPT-11) HIGH-DOSE ESCALATION USING INTENSIVE HIGH-DOSE LOPERAMIDE TO CONTROL DIARRHEA
    Journal of the National Cancer Institute
    
    D. Abigerges et al., "IRINOTECAN (CPT-11) HIGH-DOSE ESCALATION USING INTENSIVE HIGH-DOSE LOPERAMIDE TO CONTROL DIARRHEA", Journal of the National Cancer Institute, 86(6), 1994, pp. 446-449